Barkus E, Lewis S (2008). Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychological Medicine. Published online: 21 January 2008. doi:10.1017/S0033291707002619.
Barkus E, Stirling J, Hopkins R, Lewis S (2006). Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39, 139–178.
D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieve R, Krystal JH (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for research. Neuropsychopharmacology 29, 1558–1572.
D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J (2008). Blunted psychotomimetic and amestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology. Published online: 9 January 2008. doi:10.1038/sj.npp.1301643.
Di Forti M, Morrison PD, Butt A, Murray RM (2007). Cannabis use and psychiatric and cognitive disorders: the chicken or the egg? Current Opinion in Psychiatry 20, 228–234.
Favrat B, Ménétrey A, Augsburger M, Rothuizen LE, Appenseller M, Buclin T, Pin M, Mangin P, Giroud C (2005). Two cases of ‘cannabis acute psychosis’ following the administration of oral cannabis. BMC Psychiatry 5, 17–19.
Fergusson DM, Horwood LJ, Ridder EM (2005). Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 100, 354–366.
Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 330, 11–15.
Hickman M, Vickerman P, Macleod J, Kirkbride J, Jones PB (2007) Cannabis and schizophreia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia. Addiction 102, 597–606.
Mason OJ, Morgan CJA, Stefanovic A, Curran HV (2008). The Psychotomimetic States Inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophrenia Research 103, 138–142.
Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis L (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319–328.
Morgan CJA, Curran HV (2008). Effects of cannabidiol on schizophrenia-like symptoms in cannabis users. British Journal of Psychiatry 192, 306–307.
Morgan CJA, Rossell S, Pepper F, Smart J, Blackburn J, Brandner B, Curran HV (2006). Semantic priming after ketamine acutely in healthy volunteers and following chronic self-administration in substance users. Biological Psychiatry 59, 265–272.
Raine A (1991). The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophrenia Bulletin 17, 555–564.
Skosnik PD, Spatz-Glenn L, Park S (2001). Cannabis use is associated with schizotypy and attentional disinhibition. Schizophrenia Research 48, 83–92.
Soliman A, O'Driscoll GA, Pruessner J, Holahan ALV, Boileau I, Gagnon D, Dagher A (2007). Stress-induced dopamine release in humans at risk of psychosis: a [11C]raclopride PET study. Neuropsychopharmacology. Published online: 24 October 2007. doi:10.1038/sj.npp.1301597.
UNODC (2007). World Drug Report. United Nations Office on Drugs and Crime, 2007. Vienna, Austria.
Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD (2003). Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychological Medicine 33, 23–32.
Williams JH, Wellman NA, Rawlins JNP (1996). Cannabis use correlates with schizotypy in healthy people. Addiction 91, 869–878.
Zammit S, Spurlock G, Williams H, Norton N, Williams N, O'Donovan MC, Owen MJ (2007). Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. British Journal of Psychiatry 191, 402–407.